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Abstract

Author Manuscript

The clinical manifestations of typical hemolytic uremic syndrome (HUS) encompass a wide
spectrum. Despite the potentially severe sequelae from this syndrome, treatment approaches
remain supportive. We present the clinical course of a child who contracted Shiga toxin-positive E.
coli (STEC) from a daycare center during an outbreak. Utilizing the modified Ham test which is a
rapid, serum-based functional assay used to detect activation of the alternative pathway of
complement as observed in atypical HUS, patient sera revealed evidence of increased complement
activation in the acute phase of the syndrome but not after resolution. Further, this complement
activation was attenuated by eculizumab in vitro, an effect that was replicated in vitro utilizing
Shiga toxin as a stimulus of complement activation in normal serum. Our report suggests that
complement blockade may be effective in the treatment of STEC-HUS when initiated early in the
disease. Given the epidemic nature of the disease that limits the feasibility of randomized clinical
trials, further studies are needed to determine the value of early eculizumab treatment in STECHUS.
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Introduction
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The clinical manifestations of Shiga toxin-positive E. coli hemolytic uremic syndrome
(STEC-HUS) span a wide spectrum, with some children mildly affected with minimal
symptoms to other children having a severe clinical course resulting in renal failure,
substantial neurological consequences, and even death. The care of children with STECHUS remains supportive, with no therapies available to directly treat the underlying
pathophysiology. Evidence from human [1,2] and animal [3,4] models have suggested that
complement activation may play a role in the course of STEC-HUS, although this has not
been fully characterized. Eculizumab, a C5 monoclonal antibody indicated for the treatment
of atypical HUS (microangiopathic hemolytic anemia due to complement dysregulation as a
result of acquired or genetic disorders[5]), has been used in STECHUS with reports
suggesting some benefit [6,7] and others stating no benefit [8,9]. In this report, we present
the case of a child who contracted STEC from a daycare center during an outbreak. Sera
provided for testing revealed evidence of increased complement activation in the acute phase
of the syndrome.

Case Report

Author Manuscript

The child is a 28 month old previously healthy white male who developed bloody diarrhea
after three days of fever, crampy abdominal pain, emesis, and non-bloody diarrhea. Initial
evaluation was notable for white blood cell count (WBC) 14.8 k/mm3, hemoglobin 13 g/dL,
platelets 279 k/mm3, creatinine 0.3 mg/dL and a physical exam concerning for
intussusception. Abdominal ultrasound was notable for colitis. During hospital admission,
he received intravenous fluid and morphine for pain control. He became oliguric, with acute
renal failure, anemia and thrombocytopenia noted on hospital day (HD) 3: creatinine 3.1
mg/dL, platelets 9 k/mm3, hemoglobin 5.8 g/dL. A peripheral blood smear revealed
schistocytes and severely decreased platelets, consistent with a microangiopathic hemolytic
anemia. His renal failure progressed and peritoneal dialysis (PD) was initiated on HD 5 and
continued for seven days. His peak creatinine was 5.7 mg/dL, which decreased to 0.6 mg/dL
by discharge (HD 15). He required six packed red blood cell (PRBC) transfusions to
maintain hemoglobin >6 g/dL and received two platelet transfusions, each prior to a
procedure. Three days after discharge his hemoglobin was 12 g/dL, platelets 350 k/mm3,
creatinine 0.37 mg/dL.
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He had no neurological sequelae related to underlying HUS. He had significant anorexia/
nausea throughout the hospitalization and received nasogastric tube feeds until discharge.
Stool cultures at the state laboratory were positive for Shiga toxin type 2 (STX2) consistent
with likely E. coli. An outbreak of infectious diarrhea and HUS was subsequently noted at
the patient's daycare, and the local Health Department was closely involved.
Further laboratory testing was performed after written informed consent (see Supplementary
Methods). Three samples was provided: one in the acute phase of the syndrome and two
after the resolution of the syndrome. We utilized the modified Ham test that has been
recently described as a functional assay able to detect activation of the alternative pathway
of complement observed in complement-mediated hemolytic anemias [10,11]. The test was
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performed as previously described. Briefly, this rapid and simple cell proliferation assay
detects complement-mediated cell killing in the patient serum. As shown in Figure 1A, the
acute phase sample caused increased cell killing in the modified Ham test, while the two
samples during remission showed normalization of cell killing. These findings suggest that
increased complement activation is evident in the acute phase of the disease. To further
investigate these findings, we first sought to determine whether complement inhibition with
eculizumab nullifies the effects of acute STEC-HUS serum. Therefore, we incubated STECHUS serum with serum containing eculizumab at different ratios and tested its effect on the
modified Ham test. Indeed, addition of eculizumab containing serum resulted in a
normalization of the modified Ham test results in all ratios (Figure 1B).
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Then, we tried to mimic the effect caused by STEC-HUS serum utilizing normal serum with
Shiga toxin. Recombinant STX2 from E.coli was added in normal serum. Addition of Shiga
toxin in normal serum resulted in an increase in cell killing (Figure 1C), similar to that
caused by STEC-HUS serum. To exclude the possibility of direct Shiga toxin mediated cell
lysis, we also tested the effect of Shiga toxin added in complement-inactivated normal
serum, which caused no increased in cell killing.

Discussion
Our report presents the clinical course of a child with STEC-HUS who contracted STEC
during a daycare outbreak. He had laboratory findings of increased complement activation in
the acute phase of the disease but not after the resolution of the syndrome. In addition, we
are able to show that addition of Shiga toxin in normal serum mimics the increased
complement activation seen with STEC-HUS serum. More importantly, STECHUS serum is
responsive to complement blockade by eculizumab in vitro.
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Reports on eculizumab treatment in STEC-HUS have been conflicting. In line with our
experimental data, initial and later case reports have shown efficacy of early treatment with
eculizumab in severe cases of STEC-HUS [6,7]. However, analyses of the German outbreak
and registry have not favored the use of eculizumab over other treatment options [8,9]. These
analyses are limited by their retrospective nature and lack of randomization that resulted in a
comparison between different treatment groups with different disease severities. Our in vitro
data suggests that activation of the APC plays a role in the end-organ damage of STECHUS. It does not prove that eculizumab would alter the natural history of this disease but
suggest that if eculizumab therapy is attempted in future clinical trials, it should be
administered early in the disease process.
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Another interesting observation of these studies was the benefits of antibiotic treatment that
resulted in a shorter duration of E.coli excretion. Shiga toxin attacks cells expressing
globotriosylceramide (Gb3) receptors, such as renal endothelial cells. It has multiple cellular
effects that ultimately lead to cellular damage and apoptosis [12]. Several experimental
studies have also linked Shiga toxin with complement activation in vitro. Indeed, shiga toxin
inhibits major complement regulators, complement Factor H (CFH) and CFH-related
proteins, mimicking effects caused by the loss-of-function mutations observed in atypical
HUS [2,13,14]. Shiga toxin also reduces the expression of other complement regulators,
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such CD59 and thrombomodulin [15,16]. In addition, shiga toxin seems to directly activate
complement component C3 and subsequently, the alternative pathway of complement [17].
Complement activation by shiga toxin has been also suggested by several murine models
[3,18,19]. Recently, shiga toxin has also been shown to promote podocyte injury via the
alternative complement pathway in an experimental HUS model [20]. These findings
correspond to our experimental data showing that the presence of Shiga toxin causes a dosedependent activation of complement in vitro.
In summary, our report suggests that shiga toxin is directly responsible for activating the
alternative pathway of complement. Given the epidemic nature of HUS that limits the
feasibility of randomized trials, further clinical studies are needed to evaluate early
eculizumab treatment in STEC-HUS.
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HD

hospital day

HUS

hemolytic uremic syndrome

PD

peritoneal dialysis

PRBC

packed red blood cell

STEC

Shiga toxin-positive E. coli

STX2

Shiga toxin type 2

WBC

white blood cell
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Figure 1.
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A): Complement activation in Shiga-toxin associated HUS- Increased percentage of nonviable cells in the modified Ham test was observed in the acute phase of Shiga-toxin
associated HUS (STEC-HUSa) The same patient was tested twice after resolution of the
syndrome (4 and 7 days after the first sample, symbolized as STEC-HUSb and c), showing
normalization of cell killing. The dotted line symbolizes the cut-off value (21.5% non-viable
cells) above which percentage of non-viable cells suggests increased complement activation
observed in atypical HUS. Results from two independent experiments are shown.
B): Complement activation in Shiga-toxin associated HUS- Eculizumab containing serum
(ECU) was collected within 60 minutes of eculizumab infusion from a PNH patient. ECU
was mixed with serum from the acute STEC-HUS in different percentages (50–50%, 25–
75% and 12.5–87.5% of STEC-HUS and ECU sera respectively). Total amount of serum in
J Clin Exp Nephrol. Author manuscript; available in PMC 2016 July 11.
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the assay remained unchanged (20%). Eculizumab containing serum resulted in a
normalization of the modified Ham test results in all ratios. Results from two independent
experiments are shown.
C): Complement activation in Shiga-toxin associated HUS- Recombinant shiga-toxin 2 from
E.coli was added in normal serum (NS) to replicate the effects of STEC-HUS. Addition of
shiga-toxin (stx) resulted in increased percentage of non-viable cells compared to normal
serum alone and with heat-inactivated shiga-toxin (hi-stx), as well as heat-inactivated normal
serum (HNS) with maximum amount of shiga-toxin. Results from two independent
experiments are shown.
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